Scientists
at UB and Therex Technologies Inc. have developed a remarkably versatile,
antibacterial compound with anti-inflammatory properties that they are
investigating as a potential topical treatment for acne and gingivitis,
and as a preventive agent for skin cancer.
Trifluorosal,
which comes from the same class of compounds as aspirin, will be evaluated
in a clinical trial as an acne treatment beginning early next year under
a $750,000 SBIR (Small Business Innovation Research) grant from the
National Institute of Arthritis and Musculoskeletal and Skin Diseases
to Therex.
Under
a $100,000 grant from the National Cancer Institute, Trifluorosal also
will undergo Phase I studies to examine the feasibility of developing
it as a preventive agent for skin cancer.
Therex
is a graduate of the UB Technology Incubator and a subsidiary of OmniPharm
Inc., another graduate of the incubator.
It previously
was awarded grants totaling $650,000 from the National Institute of
Dental and Craniofacial Research to investigate the same compound's
potential for treating gingivitis.
"If it
turns out to be useful for several of these indications, the market
potential for Trifluorosal is at the billion-dollar level," said Joseph
Dunn, president of Therex, and research associate professor in the Department
of Oral Biology in the School of Dental Medicine. "If it turns out only
to be useful in the application with the smallest market, then its potential
is still in the hundreds of millions."
Developed
and patented by UB researchers in the School of Pharmacy and Pharmaceutical
Sciences and the School of Dental Medicine, Trifluorosal was licensed
to Therex.
In exchange
for exclusive rights to the compound, UB has retained 5 percent ownership
of Therex, and will receive royalties from sales of any products that
result.
Dunn cautioned
that there is a long way to go if the compound is deemed marketable.
He noted that the road from a New Drug Application to the marketplace
takes three to five years per drug per indication for a drug. It also
takes anywhere from $25 million to $400 million in funding, a cost that
makes partnering with a major company a necessity.
Two major
U.S. pharmaceutical companies already have expressed interest in Trifluorosal.
UB researchers
identified the chemical precursor to Trifluorosal while conducting federally
funded research in which they were searching for antibacterial compounds
in products already on the market that adhered well to skin or mucous
membranes.
The idea
was that if such compounds became the basis for new treatments, they
likely would be safe, explained Robert J. Genco, SUNY Distinguished
Professor and chair of the Department of Oral Biology, since they already
were on the market and were designed to be active only at the surface
and not absorbed into the body.
Genco
and colleagues found the precursor in shampoos and soaps, then modified
it and developed Trifluorosal. Further work by UB and Therex researchers
has resulted in a second generation of active compounds.
"Trifluorosal
is an antibacterial agent, but since it is not an antibiotic, it has
a very low potential for producing bacterial resistance," said Genco.
"At the same time, it is an anti-inflammatory agent and has a molecular
structure similar to aspirin and its toxicity is extremely low. It is
a member of the salicylanilide-type of agents, which bind strongly to
skin and mucous membranes."
Genco
and his co-researchers, Robert Coburn, professor of chemistry, and Richard
Todd Evans, professor of oral biologyand both principals with Therexinitially
were interested in the compound as a dental plaque inhibitor.
"Trifluorosal
is as effective in inhibiting plaque and gingivitis as chlorhexidine,
the most effective compound now on the market," said Genco. "However,
Trifluorosal does not have the bad taste and tendency to stain teeth
that characterizes chlorhexidine."
The researchers
later found that it also kills the bacteria that cause acne.
After
Therex licensed the compound from UB, the company's researchers found
it also absorbed ultraviolet light and enhanced the repair of skin damage
caused by sunlight, and therefore may be an important ingredient in
lotions that prevent sunburn and skin cancer.
"The beauty
of this agent is that it's very effective when applied topically, so
we looked for diseases that could be treated or prevented this way,"
Dunn explained. "It is the inflammatory component that connects these
diseases and what may turn sunburn into skin cancer."
The company
simultaneously is investigating the applications for acne, skin cancer
and gingivitis.
"We're
investigating several therapeutic tracks in parallel since there is
a lot of overlap in this research," said Genco. "So that makes it a
very efficient research program.
"UB has
been very supportive by working to patent these developments, by taking
an equity position in Therex and by fostering development of this local
company," said Genco.
Therex
also has licensed two chemical libraries for drug screening from UB
and to date has developed and filed patents for a drug candidate from
one of them that shows significant promise for treating multi-drug-resistant
breast cancer.